SPOTLIGHT -
Slideshow
Author(s):
A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.
Investigating the SAINT iTBS Protocol for Bipolar I Depression
Blue Light, Depression, and Bipolar Disorder
New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia
Four Myths About Lamotrigine
BHV-7000 for Bipolar Disorder Fails in Phase 2/3 Trial
Agree to Disagree: A Collaborative Perspective From a Treatment Team and Disagreeing Patient